Abstract
The 2024 FASEB Scientific Research Conference on NAD Metabolism and Signaling was held in Lisbon, Portugal and served to (1) unite researchers, clinicians, and trainees, (2) create opportunities for early-stage investigators by showcasing their work on an international stage and promote collaborations, (3) train the next generation of scientists in the field, and (4) improve human health by furthering our understanding of NAD(+) metabolism and signaling. With the burgeoning potential of NAD(+) as a therapeutic agent for multiple health conditions, as well as many remaining scientific questions about the NAD(+) metabolome, an expert panel discussion titled "NAD(+) Health Outcomes Forum: A Call to Action" was hosted on Thursday, August 29, 2024. The main objectives were to discuss and translate what is known about NAD(+) biology into tangible actions and to identify what remains unknown into a research call to action. Given the broad and reaching impact of NAD(+) on health, there is significant interest in NAD(+) pathway modulation, including through precursors such as nicotinic acid, nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). There is also growing research regarding the heterogeneity among individuals, as well as differences and similarities among the NAD(+) precursors, specifically in relation to dosing, timing, and their impact on various health conditions.